FR14C0016I2 - Vacccin west nile - Google Patents

Vacccin west nile

Info

Publication number
FR14C0016I2
FR14C0016I2 FR14C0016C FR14C0016C FR14C0016I2 FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2 FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2
Authority
FR
France
Prior art keywords
west nile
nile vaccine
vaccine
west
nile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0016C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis W LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W LLC filed Critical Zoetis W LLC
Publication of FR14C0016I1 publication Critical patent/FR14C0016I1/fr
Application granted granted Critical
Publication of FR14C0016I2 publication Critical patent/FR14C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR14C0016C 2001-07-27 2014-02-21 Vacccin west nile Active FR14C0016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
FR14C0016I1 FR14C0016I1 (enExample) 2014-03-28
FR14C0016I2 true FR14C0016I2 (fr) 2015-07-24

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0016C Active FR14C0016I2 (fr) 2001-07-27 2014-02-21 Vacccin west nile

Country Status (24)

Country Link
US (8) US7153513B2 (enExample)
EP (3) EP2281572A1 (enExample)
JP (2) JP4718778B2 (enExample)
KR (2) KR20040028952A (enExample)
CN (2) CN1935258B (enExample)
AU (1) AU2002365244B2 (enExample)
BE (1) BE2014C006I2 (enExample)
BR (1) BRPI0211492B1 (enExample)
CA (1) CA2452545C (enExample)
CY (1) CY2014010I2 (enExample)
DK (1) DK1427444T3 (enExample)
ES (1) ES2435095T3 (enExample)
FR (1) FR14C0016I2 (enExample)
HR (1) HRP20040195B1 (enExample)
HU (2) HU228690B1 (enExample)
LU (1) LU92348I2 (enExample)
ME (1) ME00491B (enExample)
MX (1) MXPA04000680A (enExample)
NZ (3) NZ531265A (enExample)
PL (2) PL212212B1 (enExample)
PT (1) PT1427444E (enExample)
RS (1) RS53184B (enExample)
WO (1) WO2003061555A2 (enExample)
ZA (1) ZA200401596B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
KR20040028952A (ko) * 2001-07-27 2004-04-03 와이어쓰 웨스트 나일 백신
US7585621B2 (en) * 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
CA2601705A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2007002470A2 (en) 2005-06-24 2007-01-04 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
BRPI0617735B1 (pt) * 2005-10-19 2022-05-17 University Of Florida Research Foundation Inc Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
CA2881717C (en) * 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
CN104043116A (zh) * 2007-11-06 2014-09-17 硕腾W有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
CA2735164C (en) 2008-08-29 2021-08-31 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
MX2012004133A (es) * 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
ES2894138T3 (es) * 2013-05-14 2022-02-11 Zoetis Services Llc Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes
CN109078179A (zh) * 2013-09-05 2018-12-25 硕腾服务有限责任公司 Hendra和Nipah病毒G糖蛋白免疫原性组合物
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
BR112021016182A2 (pt) 2019-02-27 2021-11-03 Univ Kentucky Res Found Composição imunológica multivalente, e, método para induzir uma resposta imune contra uma pluralidade de vírus da influenza equina

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
ATE195255T1 (de) * 1994-05-10 2000-08-15 American Home Prod Modifizierter,verbesserter,lebender brsv impfstoff
JP4489943B2 (ja) 1998-06-04 2010-06-23 アメリカ合衆国 フラビウイルス感染の予防のための核酸ワクチン
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU1152402A (en) * 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
KR20040028952A (ko) * 2001-07-27 2004-04-03 와이어쓰 웨스트 나일 백신
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
BE2014C006I2 (enExample) 2021-02-04
KR20040028952A (ko) 2004-04-03
US7153513B2 (en) 2006-12-26
ZA200401596B (en) 2005-07-27
US7648705B2 (en) 2010-01-19
PL368535A1 (en) 2005-04-04
BRPI0211492B1 (pt) 2016-06-21
LU92348I9 (enExample) 2019-01-02
ME00491B (me) 2011-10-10
US20070231349A1 (en) 2007-10-04
WO2003061555A3 (en) 2004-04-15
US20070166326A1 (en) 2007-07-19
NZ553165A (en) 2008-09-26
HUP0401606A3 (en) 2005-02-28
CY2014010I1 (el) 2020-05-29
US20070166802A1 (en) 2007-07-19
KR20090053967A (ko) 2009-05-28
BR0211492A (pt) 2004-08-17
CN1935258B (zh) 2013-04-03
PL398575A1 (pl) 2012-06-18
CN1273189C (zh) 2006-09-06
JP2011057692A (ja) 2011-03-24
HRP20040195B1 (hr) 2014-07-18
DK1427444T3 (da) 2013-11-04
LU92348I2 (fr) 2014-09-22
CN1935258A (zh) 2007-03-28
HUS1300055I1 (hu) 2016-08-29
FR14C0016I1 (enExample) 2014-03-28
NZ531265A (en) 2008-08-29
PL212212B1 (pl) 2012-08-31
CA2452545C (en) 2015-06-09
HK1066470A1 (en) 2005-03-24
MXPA04000680A (es) 2004-04-05
JP4718778B2 (ja) 2011-07-06
WO2003061555A2 (en) 2003-07-31
NZ570270A (en) 2010-08-27
AU2002365244B2 (en) 2007-12-06
US20070166324A1 (en) 2007-07-19
PL220846B1 (pl) 2016-01-29
US20070231350A1 (en) 2007-10-04
YU8004A (sh) 2006-08-17
CY2014010I2 (el) 2024-02-16
US20070178119A1 (en) 2007-08-02
HUP0401606A2 (hu) 2004-11-29
CN1535157A (zh) 2004-10-06
US7648706B2 (en) 2010-01-19
EP2283858A2 (en) 2011-02-16
HRP20040195A2 (en) 2004-08-31
US20030091595A1 (en) 2003-05-15
HU228690B1 (en) 2013-05-28
EP2281572A1 (en) 2011-02-09
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
EP2283858A3 (en) 2011-03-23
US7445787B2 (en) 2008-11-04
CA2452545A1 (en) 2003-07-31
RS53184B (sr) 2014-06-30
EP1427444A4 (en) 2008-01-02
JP2005515236A (ja) 2005-05-26
ES2435095T3 (es) 2013-12-18
US20070166325A1 (en) 2007-07-19
PT1427444E (pt) 2013-11-19

Similar Documents

Publication Publication Date Title
FR14C0016I2 (fr) Vacccin west nile
DK1390066T3 (da) Vaccinesammensætning
LU93048I2 (fr) Proteq west nile
NO20031483L (no) Vaksine
PL363005A1 (pl) Szczepionki
DE60230760D1 (de) Grippe-impfstoffzusammensetzung
NO20034683D0 (no) Intradermal vaksineinnretning
NO20024172D0 (no) Vaksine
DE60239828D1 (de) Ür
IS7291A (is) Merkt kirni
NO20026175L (no) Vaksinesammensetning
IS7297A (is) Streptococcis Pneumoniae bóluefni
NO20031705L (no) Vaksiner
IS7547A (is) Ónæmisvaldandi samsetningar
NO20033882D0 (no) Vaksine
EP1423141A4 (en) VACCINE
IS7831A (is) Bóluefni
DE60328408D1 (de) Impfstoff
NO20034165D0 (no) Forankringshylse
NO20051561D0 (no) Vaksine
DE10290185D2 (de) Tumorvakzine
SE0103415D0 (sv) Hållaranordning
SE0100410D0 (sv) Hållaranordning
SE0103470D0 (sv) Hållaranordning
FI5103U1 (fi) Salibandymaila